Revenue: As of FY2025 Q3, the actual value is USD 6.988 M.

EPS: As of FY2025 Q3, the actual value is USD -0.62.

EBIT: As of FY2025 Q3, the actual value is USD -6.167 M.

Segment Revenue

• Total revenues for the third quarter of 2025 were $7.0 million, a decrease from $9.0 million in the third quarter of 2024, reflecting a 22% year-over-year decline due to advanced purchases ahead of the October 2024 price increase.
• Total revenues for the first nine months of 2025 were $24.6 million, slightly down from $24.8 million for the same period in 2024.

Operational Metrics

• Operating expenses decreased by 5% year-over-year in the third quarter of 2025 compared to the third quarter of 2024.
• Cost of revenues decreased by $2.8 million, or 58%, compared to the three months ended September 30, 2024, primarily due to reduced Ameluz costs agreed upon with Biofrontera AG.
• Selling, general, and administrative expenses were $10.4 million for the third quarter of 2025, up from $8.4 million in the third quarter of 2024, driven by increased legal costs due to patent claims.
• Net loss for the third quarter of 2025 was $6.6 million, compared to a net loss of $5.7 million for the prior-year quarter.
• Adjusted EBITDA for the third quarter of 2025 was - $6.0 million compared to - $4.6 million for the third quarter of 2024.

Cash Flow

• Cash balance was $3.4 million as of September 30, 2025.

Unique Metrics

• The purchase of all Ameluz and RhodoLED US Assets from Biofrontera AG included a new earnout structure reducing payment rates to 12%–15% of U.S. net sales from 25%–35%.

Outlook / Guidance

• Biofrontera Inc. anticipates substantial fourth quarter and year-over-year annual revenue growth, supported by growing demand for Ameluz-PDT treatment.
• The company is positioned for sustained growth and profitability due to a revamped commercial approach and recent transactions enhancing gross margins.
• The acquisition of U.S. rights for Ameluz and RhodoLED lamps is expected to significantly enhance long-term profitability.